Report Categories
View AllRecent Articles
View All
What Magnera Corporation MAGN has done differently this quarter Q1 2026 Profit Disappoints
TXMD TherapeuticsMD Inc posts far wider Q3 2023 loss than expected with shares dipping 048 in todays trading
FTI TechnipFMC plc Ordinary Share Q4 2025 earnings beat expectations revenue rises 93 percent year over year
SVAQW Silicon quarterly earnings figures remain undisclosed as investors await full official operational updates
OIO OIO Group cites fastgrowing emerging market demand as key growth driver in latest quarterly earnings
The competitive moat visible in Arqit Quantum ARQQW earnings ARQQW Quarterly Earnings Arqit Quantum Warrants Lack Revenue EPS Data
The working capital efficiency at Amer Tower AMT Q1 2026 EPS Tops Views
Artificial Intelligence and Quarterly Earnings Reports A Macro Perspective from The Big Picture
Palantir Criticizes London Mayor Over Blocked 50 Million Police AI Contract
Post Office Horizon Scandal Police Inquiry Faces FiveYear Delay Without Additional Funding
Cerebras IPO Delivers Strong Debut ETFs Provide LowerRisk AI Chip Exposure
South Koreas Deputy PM Stresses AI Wealth Must Benefit Public Amid Samsung Labor Disputes
UK Exports to US Drop 25 Following Trumps Liberation Day Tariff Measures
Customers Bancorp CUBI Q1 2026 Earnings EPS Beat Highlights Profitability Resilience
BHFAO Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Movement
Moderna Inc MRNA Q1 2026 Earnings Narrowerthanexpected loss as cost controls offset revenue headwinds
Champions Oncology CSBR Q1 2026 Earnings EPS Misses by Wide Margin as Company Posts Loss
Everus Construction Group ECG Q1 2026 Earnings Strong EPS Beat Drives Investor Caution
Infinity Natural Resources Inc INR Q1 2026 Earnings Massive Earnings Beat Amid Cost Improvements
Eagle Bancorp EGBN Surges 28 as Buyers Reclaim Key Support
Lionsgate Studios LION Gains 186 as Stock Approaches Key Resistance Level
Fabrinet FN Sees Minor Pullback Holds Above Key Support Amid Sector Evaluation
Ziff Davis ZD Holds Near Support Amid Minimal Price Movement
Amylyx Pharmaceuticals AMLX Slips 25 as Biotech Sector Faces Renewed Scrutiny